Phosphodiesterase 5 inhibitors: current status and potential applications

[1]  T. Costigan,et al.  P-302: Blood pressure and cardiovascular effects of tadalafil, a new PDE5 inhibitor , 2002 .

[2]  T. Costigan,et al.  P-313: Efficacy and safety of tadalafil in men with erectile dysfunction with and without hypertension , 2002 .

[3]  T. Lampe,et al.  Imidazo[5,1-f][1,2,4]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors , 2002 .

[4]  H. Porst IC351 (tadalafil, Cialis): update on clinical experience , 2002, International Journal of Impotence Research.

[5]  Y. Nomoto,et al.  KF31327, a new potent and selective inhibitor of cyclic nucleotide phosphodiesterase 5. , 2001, European journal of pharmacology.

[6]  C. Sobey Cerebrovascular Dysfunction After Subarachnoid Haemorrhage: Novel Mechanisms And Directions For Therapy , 2001, Clinical and experimental pharmacology & physiology.

[7]  D. Ryu,et al.  Synthesis and phosphodiesterase inhibitory activity of new sildenafil analogues containing a carboxylic acid group in the 5'-sulfonamide moiety of a phenyl ring. , 2001, Bioorganic & medicinal chemistry.

[8]  T. Sekizawa,et al.  FR226807: a potent and selective phosphodiesterase type 5 inhibitor. , 2001, European journal of pharmacology.

[9]  J. Macor,et al.  The discovery of novel, potent and selective PDE5 inhibitors. , 2001, Bioorganic & medicinal chemistry letters.

[10]  G. Sybrecht,et al.  Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[11]  I. Goldstein,et al.  The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial , 2001, International Journal of Impotence Research.

[12]  J. Ryu,et al.  Synthesis and phosphodiesterase 5 inhibitory activity of new 5-phenyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one derivatives containing an N-acylamido group phenyl ring. , 2001, Bioorganic & medicinal chemistry.

[13]  H. Inoue,et al.  T-1032, a novel specific phosphodiesterase type 5 inhibitor, increases venous compliance in anesthetized rats. , 2001, European journal of pharmacology.

[14]  J. Kotera,et al.  Novel, potent, and selective phosphodiesterase 5 inhibitors: synthesis and biological activities of a series of 4-aryl-1-isoquinolinone derivatives. , 2001, Journal of medicinal chemistry.

[15]  S. Lee,et al.  Synthesis and phosphodiesterase 5 inhibitory activity of novel phenyl ring modified sildenafil analogues. , 2001, Bioorganic & medicinal chemistry.

[16]  L. Lupo,et al.  Premenopausal women affected by sexual arousal disorder treated with sildenafil: a double‐blind, cross‐over, placebo‐controlled study , 2001, BJOG : an international journal of obstetrics and gynaecology.

[17]  W. Klaus,et al.  Modulation of Human Platelet Aggregation by the Phosphodiesterase Type 5 Inhibitor Sildenafil , 2001, Journal of cardiovascular pharmacology.

[18]  S. Chong,et al.  Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile dysfunction. , 2001, Journal of medicinal chemistry.

[19]  M. Bortolotti,et al.  Sildenafil inhibits gastroduodenal motility , 2001, Alimentary pharmacology & therapeutics.

[20]  R. Engelmann,et al.  Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study , 2001, World Journal of Urology.

[21]  H. Inoue,et al.  Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. , 2001, European journal of pharmacology.

[22]  K. Fujishige,et al.  Characterization and effects of methyl-2- (4-aminophenyl)-1, 2-dihydro-1-oxo-7- (2-pyridinylmethoxy)-4-(3,4, 5-trimethoxyphenyl)-3-isoquinoline carboxylate sulfate (T-1032), a novel potent inhibitor of cGMP-binding cGMP-specific phosphodiesterase (PDE5). , 2000, Biochemical pharmacology.

[23]  W. Kim,et al.  Erectogenic effect of the selective phosphodiesterase type 5 inhibitor, DA-8159 , 2000, Archives of pharmacal research.

[24]  I. Goldstein,et al.  Sildenafil augments pelvic nerve‐mediated female genital sexual arousal in the anesthetized rabbit , 2000, International Journal of Impotence Research.

[25]  S. Kurowski,et al.  Sildenafil relaxes rabbit clitoral corpus cavernosum. , 2000, Life sciences.

[26]  J. Corbin,et al.  Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. , 2000, European journal of biochemistry.

[27]  J. Beavo,et al.  Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. , 2000, Current opinion in cell biology.

[28]  J. Beavo,et al.  Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Macor,et al.  N-3-substituted imidazoquinazolinones: potent and selective PDE5 inhibitors as potential agents for treatment of erectile dysfunction. , 2000, Journal of medicinal chemistry.

[30]  T. Lue,et al.  Expression of three isoforms of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in human penile cavernosum. , 2000, Biochemical and biophysical research communications.

[31]  M. Bortolotti,et al.  Effects of sildenafil on esophageal motility of patients with idiopathic achalasia. , 2000, Gastroenterology.

[32]  K. Murray,et al.  A cyclic nucleotide PDE5 inhibitor corrects defective mucin secretion in submandibular cells containing antibody directed against the cystic fibrosis transmembrane conductance regulator protein , 1999, FEBS letters.

[33]  J. Corbin,et al.  Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. , 1999, Molecular pharmacology.

[34]  J. Corbin,et al.  Cyclic GMP Phosphodiesterase-5: Target of Sildenafil* , 1999, The Journal of Biological Chemistry.

[35]  C. Conti,et al.  Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease. , 1999, The American journal of cardiology.

[36]  S. Kaplan,et al.  Safety and efficacy of sildenafil in postmenopausal women with sexual dysfunction. , 1999, Urology.

[37]  B P Gardner,et al.  Efficacy and safety of oral sildenafil (Viagra) in men with erectile dysfunction caused by spinal cord injury , 1998, Neurology.

[38]  M. Fava,et al.  An Open Trial of Oral Sildenafilin Antidepressant-Induced Sexual Dysfunction , 1998, Psychotherapy and Psychosomatics.

[39]  D. Price,et al.  Sildenafil: study of a novel oral treatment for erectile dysfunction in diabetic men , 1998, Diabetic medicine : a journal of the British Diabetic Association.

[40]  K. Ferguson,et al.  Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase. , 1998, Gene.

[41]  K. Fujishige,et al.  Expression, structure and chromosomal localization of the human cGMP-binding cGMP-specific phosphodiesterase PDE5A gene. , 1998, European journal of biochemistry.

[42]  J. Corbin,et al.  Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity. , 1998, Biochemistry.

[43]  Andrew Simon Bell,et al.  Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .

[44]  W. K. Sonnenburg,et al.  The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. , 1993, The Journal of biological chemistry.

[45]  T. Lincoln,et al.  Characterization of a novel cGMP binding protein from rat lung. , 1980, The Journal of biological chemistry.

[46]  T. Wilt,et al.  Tamsulosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. , 2002, The Journal of urology.

[47]  R. Kloner,et al.  Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. , 2001, American journal of hypertension.

[48]  D. Rotella Phosphodiesterase type 5 inhibitors: Discovery and therapeutic utility , 2001 .

[49]  P. Cartwright,et al.  Granulocytic sarcoma presenting as testicular and paratesticular masses in infancy. , 2001, The Journal of urology.